Form 10-Q · Quarterly report
Gilead Sciences 10-Q, filed Aug 6, 2026
- Filed
- CIK
- 0000882095
- Accession no.
- 0000882095-26-000031
Summary
Gilead Sciences reported second-quarter 2026 total revenues of $7.8 billion, up 10% from a year earlier, with HIV product sales up 12% to $5.7 billion and COVID-19 antiviral Veklury sales down 81% to $23 million. The quarter included $11.2 billion of acquired in-process research and development expenses, mostly tied to the Arcellx, Tubulis and Ouro Medicines acquisitions.
Key points
- Total revenues rose 10% to $7.8 billion for the quarter and 7% to $14.8 billion for the six months ended June 30, 2026.
- HIV product sales increased 12% to $5.7 billion in the quarter, led by Biktarvy at $3.8 billion and Descovy at $967 million, while Yeztugo reached $232 million.
- Veklury sales fell 81% to $23 million on lower COVID-19-related hospitalizations; cell therapy sales fell 14% to $417 million and Trodelvy rose 26% to $457 million.
- Acquired in-process research and development expenses were $11.2 billion for the quarter, including $7.0 billion for Arcellx, $3.1 billion for Tubulis and $1.0 billion for Ouro Medicines; R&D expenses rose 18% to $1.8 billion.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. MANAGEMENT’S DISCUSSION Results of Operations Revenues The following table summarizes our Total revenues and period-over-period changes: Three Months Ended June 30, 2026 Three Months Ended June 30, 2025 (in millions, except percentages) U.S. Europe Rest of World Total U.S. Europe Rest of World Total Change Product sales: HIV Biktarvy $ 2,981 $ 468 $ 323 $ 3,772 $ 2,799 $ 429 $ 302 $ 3,530 7 % Descovy 921 23 23 967 601 24 28 653 48 % Genvoya 236 37 16 289 322 40 16 377 (23) % Odefsey 171 58 10 239 221 66 11 298 (20) % Symtuza - Revenue share(1) 105 30 3 138 88 33 3 124 11 % Yeztugo 223 — 9 232 15 — — 15 NM Other HIV(2) 23 24 10 56 50 33 9 92 (39) % Total HIV 4,659 640 393 5,693 4,096…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.